Incyte Corporation (INCY)
USD 58.34
(-3.71%)
USD 58.34
(-3.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 620.52 Million USD | 7.09% |
| 2022 | 579.44 Million USD | -1.08% |
| 2021 | 585.77 Million USD | 343.78% |
| 2020 | -240.29 Million USD | -159.77% |
| 2019 | 402 Million USD | 211.09% |
| 2018 | 129.22 Million USD | 153.02% |
| 2017 | -243.73 Million USD | -268.09% |
| 2016 | 144.99 Million USD | 186.27% |
| 2015 | 50.65 Million USD | 1154.35% |
| 2014 | -4.8 Million USD | 70.17% |
| 2013 | -16.1 Million USD | -1502.61% |
| 2012 | 1.14 Million USD | 100.8% |
| 2011 | -143.18 Million USD | -1119.17% |
| 2010 | 14.04 Million USD | 110.05% |
| 2009 | -139.76 Million USD | 12.26% |
| 2008 | -159.28 Million USD | -86.78% |
| 2007 | -85.28 Million USD | -10.95% |
| 2006 | -76.86 Million USD | 23.73% |
| 2005 | -100.78 Million USD | 32.29% |
| 2004 | -148.85 Million USD | 0.3% |
| 2003 | -149.29 Million USD | -52.49% |
| 2002 | -97.9 Million USD | -51.33% |
| 2001 | -64.69 Million USD | -3.37% |
| 2000 | -62.59 Million USD | -131.81% |
| 1999 | -27 Million USD | -321.31% |
| 1998 | 12.2 Million USD | 64.86% |
| 1997 | 7.4 Million USD | 225.42% |
| 1996 | -5.9 Million USD | 46.36% |
| 1995 | -11 Million USD | 9.09% |
| 1994 | -12.1 Million USD | -146.94% |
| 1993 | -4.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -477.23 Million USD | -619.31% |
| 2024 Q3 | 146.08 Million USD | 130.61% |
| 2024 Q1 | 91.89 Million USD | -50.93% |
| 2023 Q1 | 90.45 Million USD | -12.06% |
| 2023 FY | 620.52 Million USD | 7.09% |
| 2023 Q4 | 187.27 Million USD | -12.78% |
| 2023 Q2 | 193.78 Million USD | 114.23% |
| 2023 Q3 | 214.7 Million USD | 10.8% |
| 2022 FY | 579.44 Million USD | -1.08% |
| 2022 Q1 | 116.54 Million USD | 5.24% |
| 2022 Q2 | 254.43 Million USD | 118.32% |
| 2022 Q3 | 138.37 Million USD | -45.61% |
| 2022 Q4 | 102.85 Million USD | -25.67% |
| 2021 FY | 585.77 Million USD | 343.78% |
| 2021 Q4 | 110.73 Million USD | -52.96% |
| 2021 Q2 | 140.83 Million USD | 42.55% |
| 2021 Q3 | 235.41 Million USD | 67.15% |
| 2021 Q1 | 98.79 Million USD | -39.84% |
| 2020 Q4 | 164.22 Million USD | 2983.53% |
| 2020 FY | -240.29 Million USD | -159.77% |
| 2020 Q1 | -664 Million USD | -798.89% |
| 2020 Q2 | 230.77 Million USD | 134.75% |
| 2020 Q3 | 5.32 Million USD | -97.69% |
| 2019 Q1 | 74.07 Million USD | -9.64% |
| 2019 Q4 | 95 Million USD | -29.27% |
| 2019 FY | 402 Million USD | 211.09% |
| 2019 Q3 | 134.31 Million USD | 36.21% |
| 2019 Q2 | 98.61 Million USD | 33.13% |
| 2018 Q4 | 81.97 Million USD | 163.42% |
| 2018 FY | 129.22 Million USD | 153.02% |
| 2018 Q3 | 31.11 Million USD | -62.61% |
| 2018 Q1 | -67.11 Million USD | 49.38% |
| 2018 Q2 | 83.23 Million USD | 224.03% |
| 2017 FY | -243.73 Million USD | -268.09% |
| 2017 Q1 | -133.3 Million USD | -416.79% |
| 2017 Q2 | 7.2 Million USD | 105.4% |
| 2017 Q3 | 14.95 Million USD | 107.75% |
| 2017 Q4 | -132.58 Million USD | -986.4% |
| 2016 Q3 | 22.29 Million USD | -50.01% |
| 2016 Q2 | 44.58 Million USD | 23.72% |
| 2016 FY | 144.99 Million USD | 186.27% |
| 2016 Q4 | 42.07 Million USD | 88.76% |
| 2016 Q1 | 36.03 Million USD | -44.62% |
| 2015 Q4 | 65.08 Million USD | 64535.64% |
| 2015 Q3 | -101 Thousand USD | 98.63% |
| 2015 Q1 | -6.93 Million USD | 72.94% |
| 2015 FY | 50.65 Million USD | 1154.35% |
| 2015 Q2 | -7.39 Million USD | -6.62% |
| 2014 FY | -4.8 Million USD | 70.17% |
| 2014 Q4 | -25.62 Million USD | -136.64% |
| 2014 Q3 | 69.94 Million USD | 367.09% |
| 2014 Q2 | -26.18 Million USD | -14.18% |
| 2014 Q1 | -22.93 Million USD | -42.07% |
| 2013 FY | -16.1 Million USD | -1502.61% |
| 2013 Q2 | 17.31 Million USD | 522.72% |
| 2013 Q1 | -4.09 Million USD | -113.54% |
| 2013 Q4 | -16.14 Million USD | -22.45% |
| 2013 Q3 | -13.18 Million USD | -176.12% |
| 2012 FY | 1.14 Million USD | 100.8% |
| 2012 Q2 | 15.21 Million USD | 144.52% |
| 2012 Q1 | -34.18 Million USD | 22.54% |
| 2012 Q4 | 30.25 Million USD | 398.42% |
| 2012 Q3 | -10.13 Million USD | -166.61% |
| 2011 Q3 | -42.1 Million USD | -2.41% |
| 2011 Q1 | -15.82 Million USD | -137.4% |
| 2011 Q4 | -44.13 Million USD | -4.83% |
| 2011 FY | -143.18 Million USD | -1119.17% |
| 2011 Q2 | -41.11 Million USD | -159.8% |
| 2010 Q4 | 42.31 Million USD | 291.83% |
| 2010 Q2 | 13.62 Million USD | 168.7% |
| 2010 Q1 | -19.83 Million USD | 51.89% |
| 2010 FY | 14.04 Million USD | 110.05% |
| 2010 Q3 | -22.05 Million USD | -261.89% |
| 2009 Q2 | -32.73 Million USD | 4.4% |
| 2009 Q4 | -41.22 Million USD | -30.6% |
| 2009 FY | -139.76 Million USD | 12.26% |
| 2009 Q1 | -34.24 Million USD | 19.74% |
| 2009 Q3 | -31.56 Million USD | 3.59% |
| 2008 FY | -159.28 Million USD | -86.78% |
| 2008 Q1 | -36.12 Million USD | -31.67% |
| 2008 Q2 | -40.7 Million USD | -12.67% |
| 2008 Q3 | -39.79 Million USD | 2.24% |
| 2008 Q4 | -42.66 Million USD | -7.22% |
| 2007 Q1 | -20.28 Million USD | -3.7% |
| 2007 Q4 | -27.43 Million USD | -28.35% |
| 2007 Q3 | -21.37 Million USD | -32.05% |
| 2007 Q2 | -16.18 Million USD | 20.19% |
| 2007 FY | -85.28 Million USD | -10.95% |
| 2006 Q2 | -19.18 Million USD | 14.26% |
| 2006 Q3 | -15.75 Million USD | 17.85% |
| 2006 FY | -76.86 Million USD | 23.73% |
| 2006 Q4 | -19.55 Million USD | -24.13% |
| 2006 Q1 | -22.36 Million USD | 15.89% |
| 2005 Q4 | -26.59 Million USD | 8.73% |
| 2005 FY | -100.78 Million USD | 32.29% |
| 2005 Q2 | -27.06 Million USD | -50.39% |
| 2005 Q1 | -17.99 Million USD | 47.22% |
| 2005 Q3 | -29.13 Million USD | -7.68% |
| 2004 Q2 | -60.94 Million USD | -82.04% |
| 2004 Q1 | -33.47 Million USD | 11.98% |
| 2004 FY | -148.85 Million USD | 0.3% |
| 2004 Q3 | -20.34 Million USD | 66.62% |
| 2004 Q4 | -34.09 Million USD | -67.62% |
| 2003 Q1 | -54.27 Million USD | -189.15% |
| 2003 FY | -149.29 Million USD | -52.49% |
| 2003 Q4 | -38.03 Million USD | -26.07% |
| 2003 Q3 | -30.17 Million USD | -12.5% |
| 2003 Q2 | -26.81 Million USD | 50.59% |
| 2002 Q3 | -37.46 Million USD | -64.48% |
| 2002 FY | -97.9 Million USD | -51.33% |
| 2002 Q4 | -18.77 Million USD | 49.9% |
| 2002 Q2 | -22.77 Million USD | -20.53% |
| 2002 Q1 | -18.89 Million USD | -31.45% |
| 2001 Q1 | -21.39 Million USD | -25.5% |
| 2001 Q2 | -17.69 Million USD | 17.31% |
| 2001 Q3 | -11.22 Million USD | 36.54% |
| 2001 Q4 | -14.37 Million USD | -28.03% |
| 2001 FY | -64.69 Million USD | -3.37% |
| 2000 Q1 | -15.4 Million USD | -126.49% |
| 2000 Q3 | -15.74 Million USD | -9.41% |
| 2000 Q4 | -17.05 Million USD | -8.29% |
| 2000 FY | -62.59 Million USD | -131.81% |
| 2000 Q2 | -14.39 Million USD | 6.55% |
| 1999 Q4 | -6.8 Million USD | 35.24% |
| 1999 Q3 | -10.5 Million USD | -36.36% |
| 1999 Q2 | -7.7 Million USD | -285.0% |
| 1999 FY | -27 Million USD | -321.31% |
| 1999 Q1 | -2 Million USD | -350.0% |
| 1998 Q2 | 4.3 Million USD | 4.88% |
| 1998 Q4 | 800 Thousand USD | -73.33% |
| 1998 Q3 | 3 Million USD | -30.23% |
| 1998 Q1 | 4.1 Million USD | 20.59% |
| 1998 FY | 12.2 Million USD | 64.86% |
| 1997 FY | 7.4 Million USD | 225.42% |
| 1997 Q1 | 600 Thousand USD | 400.0% |
| 1997 Q2 | 1.5 Million USD | 150.0% |
| 1997 Q3 | 1.9 Million USD | 26.67% |
| 1997 Q4 | 3.4 Million USD | 78.95% |
| 1996 Q2 | -2.2 Million USD | 21.43% |
| 1996 Q3 | -700 Thousand USD | 68.18% |
| 1996 Q4 | -200 Thousand USD | 71.43% |
| 1996 FY | -5.9 Million USD | 46.36% |
| 1996 Q1 | -2.8 Million USD | -12.0% |
| 1995 Q1 | -2.2 Million USD | 48.84% |
| 1995 Q4 | -2.5 Million USD | 19.35% |
| 1995 Q3 | -3.1 Million USD | 0.0% |
| 1995 Q2 | -3.1 Million USD | -40.91% |
| 1995 FY | -11 Million USD | 9.09% |
| 1994 Q3 | -3.1 Million USD | -29.17% |
| 1994 Q2 | -2.4 Million USD | -9.09% |
| 1994 FY | -12.1 Million USD | -146.94% |
| 1994 Q1 | -2.2 Million USD | -69.23% |
| 1994 Q4 | -4.3 Million USD | -38.71% |
| 1993 FY | -4.9 Million USD | 0.0% |
| 1993 Q3 | -1.2 Million USD | 0.0% |
| 1993 Q4 | -1.3 Million USD | -8.33% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 361.596% |
| Alkermes plc | 414.12 Million USD | -49.841% |
| Agenus Inc. | -159.54 Million USD | 488.924% |
| Aptorum Group Limited | -10.52 Million USD | 5996.66% |
| Ardelyx, Inc. | -63.27 Million USD | 1080.664% |
| Dyadic International, Inc. | -8.22 Million USD | 7640.033% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 52157.466% |
| Lantern Pharma Inc. | -17.87 Million USD | 3570.969% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 3188.758% |
| Novavax, Inc. | -566.51 Million USD | 209.535% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 950.279% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 854.933% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 3295.533% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 5974.515% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 1268.017% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 263.083% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 2652.907% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 1738.609% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 581.072% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 839.477% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 3637.973% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 1509.964% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 2597.686% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 546.321% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 319.908% |
| AlloVir, Inc. | -181.33 Million USD | 442.206% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 402.692% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 2220.873% |
| Bicycle Therapeutics plc | -189.94 Million USD | 426.685% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 461.228% |
| ChromaDex Corporation | -5.59 Million USD | 11182.783% |
| Chimerix, Inc. | -93.06 Million USD | 766.765% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 1476.58% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 634.663% |
| CRISPR Therapeutics AG | -222.53 Million USD | 378.84% |
| Precision BioSciences, Inc. | -43.73 Million USD | 1518.797% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 425.716% |
| Fortress Biotech, Inc. | -142.34 Million USD | 535.939% |
| Fortress Biotech, Inc. | -142.34 Million USD | 535.939% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 735.172% |
| ImmuCell Corporation | -5.74 Million USD | 10895.348% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 561.601% |
| Immix Biopharma, Inc. | -16.14 Million USD | 3944.376% |
| Innoviva, Inc. | 176.7 Million USD | -251.156% |
| IO Biotech, Inc. | -91.44 Million USD | 778.592% |
| Jaguar Health, Inc. | -34.29 Million USD | 1909.586% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 465.141% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -5096.156% |
| ContextLogic Inc. | -328 Million USD | 289.184% |
| MiMedx Group, Inc. | 37.11 Million USD | -1571.853% |
| MEI Pharma, Inc. | 14.54 Million USD | -4167.123% |
| NextCure, Inc. | -67.63 Million USD | 1017.434% |
| Onconetix, Inc. | -36.03 Million USD | 1822.026% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 1587.57% |
| Opthea Limited | -191.84 Million USD | 423.455% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 22649.581% |
| Vaxcyte, Inc. | -468.04 Million USD | 232.579% |
| PDS Biotechnology Corporation | -43.04 Million USD | 1541.565% |
| Precigen, Inc. | -88.92 Million USD | 797.823% |
| Pharming Group N.V. | -4.87 Million USD | 12816.865% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 470.879% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 2185.378% |
| PureTech Health plc | -146.19 Million USD | 524.439% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 3128.281% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 363.383% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 2652.907% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 326.465% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 2217.471% |
| Acelyrin, Inc. | -422.06 Million USD | 247.022% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 4812258.878% |
| Summit Therapeutics Inc. | -89.73 Million USD | 791.501% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 1774.199% |
| Senti Biosciences, Inc. | -92.72 Million USD | 769.196% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 640.654% |
| Elevation Oncology, Inc. | -45.44 Million USD | 1465.442% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 1910.853% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 15841.183% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 19724.447% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 1979.183% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 7399.435% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 1012.59% |
| Seer, Inc. | -103.46 Million USD | 699.755% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 1043.635% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 962.643% |
| ESSA Pharma Inc. | -32.13 Million USD | 2031.048% |
| GlycoMimetics, Inc. | -39.27 Million USD | 1679.937% |
| GT Biopharma, Inc. | -13.57 Million USD | 4670.75% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 383.059% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 1441.502% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -614.792% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 1193.263% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 1304.763% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 6344.186% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 223.043% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 9095.723% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 1324.084% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 338.977% |
| Aptose Biosciences Inc. | -52.35 Million USD | 1285.203% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 4402.994% |
| Soligenix, Inc. | -7.69 Million USD | 8160.923% |
| Century Therapeutics, Inc. | -146.54 Million USD | 523.434% |
| Kura Oncology, Inc. | -165.8 Million USD | 474.252% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 763.961% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 7559.13% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 25104.644% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 9670.096% |
| Autolus Therapeutics plc | -195.02 Million USD | 418.172% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 832.987% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 942.395% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 3036.007% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 373.317% |
| GRI Bio, Inc. | -11.38 Million USD | 5549.416% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 13841.456% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 572.986% |
| IGM Biosciences, Inc. | -263.46 Million USD | 335.528% |
| INmune Bio, Inc. | -29.74 Million USD | 2186.43% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 660.977% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 1729.73% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 3983.29% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 4034.638% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 1115.622% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 677.114% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 324.823% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 405.378% |
| Verastem, Inc. | -92.08 Million USD | 773.868% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 1416.485% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 436.976% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 624.181% |
| Histogen Inc. | -10.64 Million USD | 5930.358% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 4110.642% |
| Surrozen, Inc. | -45.78 Million USD | 1455.45% |
| Organovo Holdings, Inc. | -15.08 Million USD | 4213.251% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 12290.496% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 1146.744% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 1309.742% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 2554.608% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 8229.671% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 462.281% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 1380.807% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 893.459% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 4176.829% |
| Apollomics, Inc. | -54.83 Million USD | 1231.643% |
| Amarin Corporation plc | -67.58 Million USD | 1018.099% |
| Mesoblast Limited | -58.79 Million USD | 1155.422% |
| Turnstone Biologics Corp. | -59.03 Million USD | 1151.167% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 474.872% |
| Synaptogenix, Inc. | -8.31 Million USD | 7563.747% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 4354.251% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 776.757% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 13050.629% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 7126.48% |
| Exelixis, Inc. | 170.88 Million USD | -263.124% |
| Better Therapeutics, Inc. | -38.26 Million USD | 1721.779% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 500.176% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 219.996% |
| NLS Pharmaceutics AG | -11.8 Million USD | 5355.541% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 7816.143% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 2168.899% |
| Gritstone bio, Inc. | -154.63 Million USD | 501.286% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 1001.127% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 3723.916% |
| Avid Bioservices, Inc. | -18.67 Million USD | 3422.224% |
| Insmed Incorporated | -709.62 Million USD | 187.444% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 4054.961% |
| MediWound Ltd. | -15.29 Million USD | 4158.371% |
| OmniAb, Inc. | -69.41 Million USD | 993.884% |
| Alector, Inc. | -151.74 Million USD | 508.94% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 674.651% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 1289.931% |
| Zai Lab Limited | -366.57 Million USD | 269.277% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 295.887% |
| Aura Biosciences, Inc. | -84.99 Million USD | 830.107% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 352.761% |
| Immunic, Inc. | -99.22 Million USD | 725.384% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 533.455% |
| Veracyte, Inc. | -85.79 Million USD | 823.265% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 320.189% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 4466.819% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 9108.853% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 3401.962% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | -7.25% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 2537.925% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -1499.209% |
| TG Therapeutics, Inc. | 20.63 Million USD | -2907.44% |
| Galecto, Inc. | -39.9 Million USD | 1655.006% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 1574.842% |
| Fortrea Holdings Inc. | 63.1 Million USD | -883.399% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 541.828% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 2248.781% |
| XBiotech Inc. | -37.51 Million USD | 1754.292% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 1001.127% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 1024.501% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 675.061% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 2517.128% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 1264.387% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 209.016% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 890.558% |
| Vaxxinity, Inc. | -58.28 Million USD | 1164.639% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 698.333% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 2888.484% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 818.067% |
| NexImmune, Inc. | -29.19 Million USD | 2225.633% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 11141.111% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 4355.599% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 84.667% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 2537.35% |
| Scopus BioPharma Inc. | -11.71 Million USD | 5396.897% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 588.364% |
| Ainos, Inc. | -13.2 Million USD | 4798.67% |
| Pluri Inc. | -22.15 Million USD | 2900.456% |
| Prothena Corporation plc | -191.03 Million USD | 424.821% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 549.532% |
| Celularity Inc. | -192.28 Million USD | 422.708% |
| Rallybio Corporation | -78.93 Million USD | 886.151% |
| Cue Biopharma, Inc. | -52.14 Million USD | 1289.908% |
| MeiraGTx Holdings plc | -137.06 Million USD | 552.736% |
| Omeros Corporation | -164.53 Million USD | 477.15% |
| Humacyte, Inc. | -100.04 Million USD | 720.233% |
| Immunocore Holdings plc | -59.64 Million USD | 1140.294% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 3443.526% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 2634.514% |
| Blueprint Medicines Corporation | -486.27 Million USD | 227.607% |
| CalciMedica, Inc. | -21.87 Million USD | 2936.686% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 931.134% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 571.936% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 462.255% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 289.821% |
| Pulmatrix, Inc. | -14.74 Million USD | 4309.803% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 1835.977% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 798.27% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 220.422% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 1018.602% |
| Cytokinetics, Incorporated | -496.2 Million USD | 225.054% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 1902.856% |
| Nutriband Inc. | -4.87 Million USD | 12836.749% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 1522.798% |
| Vor Biopharma Inc. | -126.03 Million USD | 592.339% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 85.372% |
| Evogene Ltd. | -26.39 Million USD | 2451.275% |
| ProKidney Corp. | -151.52 Million USD | 509.528% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 1061.533% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 8166.894% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 202.166% |
| CorMedix Inc. | -48.95 Million USD | 1367.469% |
| BioLineRx Ltd. | -49.69 Million USD | 1348.692% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 643.495% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 1729.872% |
| Atai Life Sciences N.V. | -125.47 Million USD | 594.557% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 860.081% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 862.231% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 349.219% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 2118.624% |
| MediciNova, Inc. | -9.9 Million USD | 6367.762% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 591.027% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 8667.877% |
| GeoVax Labs, Inc. | -26.74 Million USD | 2420.332% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 367.67% |
| Biomea Fusion, Inc. | -126.13 Million USD | 591.953% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 277.596% |
| Mereo BioPharma Group plc | -28.41 Million USD | 2283.717% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 424.731% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 369.847% |
| Absci Corporation | -115.51 Million USD | 637.181% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 2349.338% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 649.784% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 356.244% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 2562.792% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 398.338% |
| Allakos Inc. | -196.05 Million USD | 416.504% |
| Imunon, Inc. | -21.03 Million USD | 3050.605% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 660.729% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -478.406% |
| BioAtla, Inc. | -129.68 Million USD | 578.479% |
| NLS Pharmaceutics AG | -11.8 Million USD | 5355.541% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 4016.714% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 289.336% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 1586.003% |
| XOMA Corporation | -41.84 Million USD | 1582.807% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 689.645% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 610.741% |
| aTyr Pharma, Inc. | -54.91 Million USD | 1229.891% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 809.764% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 458.955% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 343.869% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 2990.734% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 7655.625% |
| Akari Therapeutics, Plc | -16.8 Million USD | 3792.283% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 7017208.389% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -83.819% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 9596.831% |
| UroGen Pharma Ltd. | -65.53 Million USD | 1046.846% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 795.048% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 8643.632% |
| Orgenesis Inc. | -53.63 Million USD | 1256.919% |
| Entera Bio Ltd. | -8.89 Million USD | 7079.249% |
| GH Research PLC | -41.22 Million USD | 1605.325% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 2513.743% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 847.143% |
| Xencor, Inc. | -138.63 Million USD | 547.583% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 12138.316% |
| Replimune Group, Inc. | -234.77 Million USD | 364.309% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 2987.355% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 4547.57% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 9596.831% |
| Portage Biotech Inc. | -18.25 Million USD | 3499.578% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 8667.877% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 691.196% |
| OncoCyte Corporation | -25.13 Million USD | 2568.67% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 5589.012% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 5516.092% |
| Purple Biotech Ltd. | 22.27 Million USD | -2686.247% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 8360.45% |
| scPharmaceuticals Inc. | -55.39 Million USD | 1220.162% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 3383.602% |
| HilleVax, Inc. | -133.34 Million USD | 565.353% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 5250.012% |
| Tharimmune, Inc. | -9.45 Million USD | 6662.777% |
| Genprex, Inc. | -31.07 Million USD | 2096.826% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 429.726% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 2077.643% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 81214.379% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 11492.22% |
| OKYO Pharma Limited | -15.74 Thousand USD | 3940008.811% |
| Savara Inc. | -60 Million USD | 1134.088% |
| Curis, Inc. | -48.33 Million USD | 1383.88% |
| Daré Bioscience, Inc. | -30.83 Million USD | 2112.086% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 11993.65% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 8627.209% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 2377.156% |
| BeiGene, Ltd. | -1.2 Billion USD | 151.379% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 3212.07% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 227.369% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 762.586% |
| Erasca, Inc. | -141.52 Million USD | 538.456% |
| bluebird bio, Inc. | -244.26 Million USD | 354.041% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 13807.28% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -219.133% |
| DBV Technologies S.A. | -76.43 Million USD | 911.865% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 13807.28% |
| Moderna, Inc. | -4.23 Billion USD | 114.638% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 1556.324% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 9856.682% |
| Molecular Templates, Inc. | -10.46 Million USD | 6028.96% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 1022.892% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 264.707% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 532.992% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 1293.478% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 501.525% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 398.143% |
| MacroGenics, Inc. | -168.24 Million USD | 468.824% |
| RenovoRx, Inc. | -11.39 Million USD | 5545.112% |
| Adicet Bio, Inc. | -152.03 Million USD | 508.138% |
| Prime Medicine, Inc. | -191.29 Million USD | 424.386% |
| Aditxt, Inc. | -26.06 Million USD | 2480.918% |
| Adagene Inc. | -23.71 Million USD | 2716.056% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 8588.6% |
| Quantum-Si incorporated | -111.17 Million USD | 658.172% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 2060.708% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 4356.653% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | -408.569% |
| SciSparc Ltd. | -5.77 Million USD | 10848.744% |
| Vericel Corporation | -6.46 Million USD | 9699.706% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 7268.177% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 2783.981% |
| Generation Bio Co. | -138.56 Million USD | 547.829% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 847.35% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 817.702% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 357.371% |
| Invivyd, Inc. | -207.78 Million USD | 398.641% |
| Relay Therapeutics, Inc. | -373 Million USD | 266.361% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 6716.46% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -2788.716% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 6132.128% |
| 2seventy bio, Inc. | -216.7 Million USD | 386.348% |
| ADMA Biologics, Inc. | 21.63 Million USD | -2768.551% |
| Clene Inc. | -40.54 Million USD | 1630.649% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 2677.16% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 1232.428% |
| GeoVax Labs, Inc. | -26.74 Million USD | 2420.332% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 277.262% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 1789.33% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -3759.706% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 698.373% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 1924.966% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 464.419% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 190.68% |
| Evaxion Biotech A/S | -22.19 Million USD | 2895.535% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 853.229% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 378.108% |
| Trevena, Inc. | -35.28 Million USD | 1858.459% |
| Surrozen, Inc. | -45.78 Million USD | 1455.45% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 876.19% |
| Cingulate Inc. | -22.75 Million USD | 2826.481% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -8182.501% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 1489.225% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 7636.185% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 705.048% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 945.644% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 1099.654% |
| Clearmind Medicine Inc. | -8.74 Million USD | 7198.732% |
| Kronos Bio, Inc. | -121.83 Million USD | 609.337% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 914.38% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 21256.774% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 715.435% |
| Statera Biopharma, Inc. | -98.34 Million USD | 730.975% |
| ImmunityBio, Inc. | -362.25 Million USD | 271.297% |
| Korro Bio, Inc. | -84.53 Million USD | 834.054% |
| Kineta, Inc. | -15.72 Million USD | 4046.607% |
| BioVie Inc. | -32.17 Million USD | 2028.319% |
| Codexis, Inc. | -68.06 Million USD | 1011.612% |
| Celularity Inc. | -192.28 Million USD | 422.708% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 378.752% |
| Celcuity Inc. | -66.23 Million USD | 1036.92% |
| Virax Biolabs Group Limited | -6.49 Million USD | 9651.721% |
| Cibus, Inc. | -318.88 Million USD | 294.593% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 1543.081% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 1933.486% |
| IN8bio, Inc. | -30.33 Million USD | 2145.44% |
| Kodiak Sciences Inc. | -277.32 Million USD | 323.757% |
| Annexon, Inc. | -143.72 Million USD | 531.751% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 601.268% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 1059.882% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 2746.839% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 275.423% |
| Eyenovia, Inc. | -25.4 Million USD | 2542.392% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -1801.118% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 11256.508% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 884.155% |
| Arcellx, Inc. | -89.88 Million USD | 790.393% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 1466.434% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 552.255% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 2094.68% |
| Moolec Science SA | -6.65 Million USD | 9425.867% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 1114.958% |
| Geron Corporation | -193.94 Million USD | 419.951% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 1534.64% |
| Royalty Pharma plc | 1.49 Billion USD | 58.414% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 477.996% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 6752.379% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 2934.138% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 462.971% |
| Humacyte, Inc. | -100.04 Million USD | 720.233% |
| Structure Therapeutics Inc. | -102.77 Million USD | 703.77% |
| 89bio, Inc. | -151.2 Million USD | 510.389% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 874.379% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 4367.71% |
| Genelux Corporation | -24.16 Million USD | 2667.867% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 1929.216% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 461.295% |
| Notable Labs, Ltd. | -14.65 Million USD | 4333.643% |
| Liquidia Corporation | -73.38 Million USD | 945.586% |
| Mustang Bio, Inc. | -50.72 Million USD | 1323.288% |
| Immunovant, Inc. | -282.7 Million USD | 319.492% |
| Quantum-Si incorporated | -111.17 Million USD | 658.172% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 894.496% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 3017.783% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 708.286% |
| Acasti Pharma Inc. | -11.31 Million USD | 5585.546% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 2807.221% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 3983.29% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 389.892% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 17012.315% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 4006.112% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 2228.22% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 1599.432% |
| PepGen Inc. | -84.76 Million USD | 832.045% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 2194.175% |
| United Therapeutics Corporation | 1.18 Billion USD | 47.631% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 2810.071% |
| Solid Biosciences Inc. | -104.31 Million USD | 694.857% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 1991.376% |
| Immuneering Corporation | -58.41 Million USD | 1162.308% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 12290.496% |
| Silo Pharma, Inc. | -3.85 Million USD | 16194.156% |
| Belite Bio, Inc | -31.66 Million USD | 2059.47% |
| XOMA Corporation | -41.84 Million USD | 1582.807% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 1019.024% |
| Bionomics Limited | -17.89 Billion USD | 103.468% |
| Apogee Therapeutics, Inc. | -93 Million USD | 767.21% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -1639.14% |
| uniQure N.V. | -282.87 Million USD | 319.367% |
| Cassava Sciences, Inc. | -105.95 Million USD | 685.639% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 8588.6% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 579.155% |
| Forte Biosciences, Inc. | -32.48 Million USD | 2010.131% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 7568.327% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 2210.988% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 11256.508% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 4466.819% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 7080.819% |
| Altimmune, Inc. | -95.92 Million USD | 746.859% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 944.321% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -1639.14% |
| Compugen Ltd. | -12.99 Million USD | 4876.208% |
| Peak Bio, Inc. | -1356.23 USD | 45753770.1% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 1350.958% |
| Benitec Biopharma Inc. | -22.49 Million USD | 2859.115% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 356.095% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 2186.079% |
| Zura Bio Limited | -62.63 Million USD | 1090.653% |
| PolyPid Ltd. | -22.86 Million USD | 2813.627% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 3912.515% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 2186.079% |
| Instil Bio, Inc. | -159.16 Million USD | 489.853% |
| argenx SE | -425.04 Million USD | 245.989% |
| Immunome, Inc. | -109.53 Million USD | 666.534% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 1332.105% |
| Verona Pharma plc | -67.83 Million USD | 1014.812% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 2481.14% |
| Shattuck Labs, Inc. | -91.95 Million USD | 774.799% |
| CervoMed Inc. | -7.81 Million USD | 8042.318% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 948.755% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 4758.246% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 1388.091% |
| Moolec Science SA | -6.65 Million USD | 9425.867% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 3872.546% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 558.878% |
| AnaptysBio, Inc. | -164.41 Million USD | 477.423% |
| Design Therapeutics, Inc. | -78.19 Million USD | 893.612% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 812.911% |
| NeurAxis, Inc. | -6.66 Million USD | 9410.908% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 1632.198% |
| Lumos Pharma, Inc. | -36.61 Million USD | 1794.775% |
| Achilles Therapeutics plc | -75.25 Million USD | 924.563% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 2481.14% |
| 180 Life Sciences Corp. | -13.47 Million USD | 4704.155% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -11934.282% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 21256.774% |
| Nutriband Inc. | -4.87 Million USD | 12836.749% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 660.142% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 1219.091% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 1320.641% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 1038.781% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 1246.507% |
| Palisade Bio, Inc. | -13.07 Million USD | 4847.705% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 1466.524% |
| Beam Therapeutics Inc. | -176.48 Million USD | 451.602% |
| Neurogene Inc. | -55.58 Million USD | 1216.394% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 668.486% |
| AEON Biopharma, Inc. | -48.42 Million USD | 1381.309% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 741.635% |
| Sesen Bio, Inc. | -25.9 Million USD | 2495.017% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 842.886% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 5029.929% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 234.733% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 956.617% |
| Athira Pharma, Inc. | -125.46 Million USD | 594.576% |
| Vaccinex, Inc. | -22.88 Million USD | 2811.492% |
| HCW Biologics Inc. | -25.71 Million USD | 2512.883% |
| XOMA Corporation | -41.84 Million USD | 1582.807% |
| Nektar Therapeutics | -137.42 Million USD | 551.537% |
| Arvinas, Inc. | -401.5 Million USD | 254.552% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 7017208.389% |
| Merus N.V. | -156.54 Million USD | 496.383% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 718.91% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 1892.389% |
| Rezolute, Inc. | -70.42 Million USD | 981.14% |
| Clene Inc. | -40.54 Million USD | 1630.649% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 3888.662% |
| BeyondSpring Inc. | -23.11 Million USD | 2784.628% |
| Synlogic, Inc. | -55.16 Million USD | 1224.934% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 3561.013% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 5832.862% |
| Peak Bio, Inc. | -1356.23 USD | 45753770.1% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 1632.047% |
| Krystal Biotech, Inc. | -109.72 Million USD | 665.517% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 579.022% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 280.904% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 13174.824% |
| MannKind Corporation | 8.67 Million USD | -7050.553% |
| Ikena Oncology, Inc. | -75.41 Million USD | 922.792% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 6532.311% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 1022.988% |
| Gossamer Bio, Inc. | -183.75 Million USD | 437.684% |
| CohBar, Inc. | -12.38 Million USD | 5108.961% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 1323.336% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 2349.338% |
| Legend Biotech Corporation | -439.48 Million USD | 241.194% |
| Mural Oncology plc | -194.63 Million USD | 418.81% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 1024.184% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 3943.386% |
| Disc Medicine, Inc. | -91.12 Million USD | 780.96% |
| Champions Oncology, Inc. | -7.35 Million USD | 8535.631% |
| REGENXBIO Inc. | -268.12 Million USD | 331.429% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 5889.459% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 1212.93% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 1692.697% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 642.621% |
| Vaxart, Inc. | -83.34 Million USD | 844.508% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 7383.15% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 1550.025% |
| Cellectis S.A. | -106.62 Million USD | 681.964% |
| Longeveron Inc. | -21.02 Million USD | 3050.806% |
| Repare Therapeutics Inc. | -116.22 Million USD | 633.904% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 331.691% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 920.312% |
| Revolution Medicines, Inc. | -487.18 Million USD | 227.369% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 9428.397% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 1511.76% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 931.914% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 991.111% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 5735.501% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 85.594% |
| Denali Therapeutics Inc. | -196.69 Million USD | 415.469% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 7268.177% |
| Veru Inc. | -93.78 Million USD | 761.666% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 2759.887% |
| Cingulate Inc. | -22.75 Million USD | 2826.481% |
| Passage Bio, Inc. | -108.38 Million USD | 672.498% |
| Context Therapeutics Inc. | -25.07 Million USD | 2574.911% |
| Exicure, Inc. | -14.99 Million USD | 4237.937% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 401.132% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 1628.462% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 6486.014% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 436.589% |
| Nuvalent, Inc. | -149.49 Million USD | 515.089% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 7652.173% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 799.333% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 3087.027% |
| OmniAb, Inc. | -69.41 Million USD | 993.884% |
| Anew Medical, Inc. | -1.3 Million USD | 47801.87% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 4958.86% |
| Lipocine Inc. | -17.93 Million USD | 3560.635% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 1005.704% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 914.851% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 1729.73% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 1669.876% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 2872.181% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 207.015% |
| Ocugen, Inc. | -65.53 Million USD | 1046.918% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 761.075% |
| Q32 Bio Inc. | -92.1 Million USD | 773.737% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 2994.375% |
| Alumis Inc. Common Stock | -158.17 Million USD | 492.305% |
| Equillium, Inc. | -14.52 Million USD | 4373.0% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 1094.335% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 7951.418% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 3389.274% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 1421.644% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 672.092% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 5283.995% |
| Dominari Holdings Inc. | -21.79 Million USD | 2946.967% |
| Edesa Biotech, Inc. | -9.22 Million USD | 6828.193% |
| vTv Therapeutics Inc. | -25.5 Million USD | 2533.241% |
| Bio-Techne Corporation | 206.68 Million USD | -200.226% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 258.505% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | -223.14% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 569.11% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 1716.329% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 510.669% |
| Nkarta, Inc. | -131.65 Million USD | 571.344% |
| BioCardia, Inc. | -11.64 Million USD | 5429.139% |
| Iterum Therapeutics plc | -47.46 Million USD | 1407.249% |